Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1

Status

Completed 6

Sponsor Class

INDUSTRY 6OTHER 4

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 2Genitourinary 2Dermatologic 1

Conditions

Multiple Myeloma 14Recurrence 6Neoplasms 6Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Neoplasms, Plasma Cell 3Lymphoma 3Leukemia 3Sezary Syndrome 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Panobinostat × Clear all
NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Novartis

Phase 2 Completed
35 enrolled 8 charts
Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00503451 2020-12-19

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
14 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT00570284 2020-12-19

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT00663832 2020-12-19

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Novartis

Phase 1 Completed
44 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00739414 2020-12-19

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
14 enrolled
Tumor-Agnostic

Neoplasms

NCT00412997 2012-11-27

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Novartis

Phase 1 Completed
14 enrolled
DermatologicLymphoid

Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡